# Surgical Treatment Versus Percutaneous Closure of Ruptured Sinus of Valsalva Aneurysm: A Systematic Review and Meta-Analysis

### Humberto Morais<sup>1\*</sup>, Hilaryano Ferreira<sup>2</sup>, Tchitchamene Nelumba<sup>3</sup>

<sup>1</sup> Department of Cardiology. Hospital Militar Principal/Instituto Superior, Luanda República de Angola <sup>2</sup> Department of Cardiology, Hospital Professor Doutor Fernando Fonseca, Lisbon, Portugal <sup>3</sup> Department of Pediatric Cardiology, Hospital Santa Cruz, Lisbon, Portugal

### Article Info

Received: February 11, 2021 Accepted: February 17, 2021 Published: February 22, 2021

\*Corresponding author: Humberto Morais , Department of Cardiology. Hospital Militar Principal/Instituto Superior Luanda Republica de Angola.

**Citation:** Humberto Morais, Hilaryano Ferreira, Tchitchamene Nelumba (2021) Surgical Treatment Versus Percutaneous Closure of Ruptured Sinus of Valsalva Aneurysm: A Systematic Review and Meta-Analysis. *Clinical Case Reports and Clinical Study*, 2(4) ; DOI: 10.61148/2766-8614/JCCRCS/026

**Copyright:** © 2021 Humberto Morais, This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

A sinus of Valsalva aneurysm may occur as a congenital or acquired defect at the junction of the aortic media and the surrounding fibrous tissue. They are generally asymptomatic until a complication sets in, thus can cause compression and or rupture of adjacent cardiac structures, resulting in symptoms which prompt urgent management. This condition may be managed surgically or percutaneously. We aim to evaluate the outcomes in surgical versus percutaneous closure of ruptured sinus of Valsalva. This Systematic review and meta-analyses statement included 254 patients, stratified in two groups, percutaneous group (70 patients) and surgical group (184 patients). Overall poor outcome occurred in 31 patients OR 0.75 (P= 0.51, I2=53%). Sub-analysis showed an occurrence of residual shunt (OR 1.71, P=0.47, I2=0%), aortic regurgitation "de novo" (OR 1.11, P=0.87), sinus of Valsalva aneurysm recurrence (OR4.28, P=0.31), pericardial effusion (OR 0.74, P=0.71, I2=0%), with a mortality OR 0.46 (CI 95% [0.08-2.75], P=0.39, I2=0%). The present study showed that when compared to surgical treatment the percutaneous closure of ruptured sinus of Valsalva is safe and effective, being an excellent alternative in selected patients.

**Keywords:** Sinus of Valsalva aneurysm; percutaneous closure; surgical treatment residual shunt; "de novo" aortic regurgitation

# Introduction

Sinus of Valsalva aneurysms (SOVAs) are rare but well-known cardiac pathologies. Congenital SOVAs is caused by absence of elastic tissue between aortic media and the annulus fibrosus. (1) Ventricular septal defect (VSD), aortic regurgitation (AR), and bicuspid aortic valve (BAV) are the most frequently lesions associated with this SOVAs type. In patients undergoing cardiac surgery, they are often seen in Asian rather than in Western populations (2). The right sinus of the Valsalva is the most frequently affected, followed by the non-coronary sinus. Aneurysms of the left sinus are rare (3).

SOVAs can be asymptomatic until a complication arises. Their most frequent complication is the aneurysm rupture into the adjacent cavities, mostly to right ventricle (fig.1) followed to right atrium (3-7). Other complications include compression of the adjacent structures, causing obstruction of the left or right ventricular outflow tract, (8,9) compression of the coronary arteries leading to angina, or myocardial infarction (10). Rarely dissection by SOVA of the interventricular septum may occur (11).

Conventional surgical repair with cardiopulmonary bypass is the most widely used repair technic of ruptured SOVAs worldwide with low mortality rates. However, morbidity may arise from cardiopulmonary bypass and thoracotomy (3-7).




Figure 1 - Transesophageal echocardiography long axis view showing rupture of right sinus of Valsalva into right ventricle (arrow)

Percutaneous treatment of SOVA rupture was first attempted by Cullen et all, in 1994 using Rashkind umbrella device in a patient who had previous cardiac surgery for a ruptured SOVA (12). Since then, several series on this type of treatment have been published, utilizing the several closure devises, with good immediate mid-term or long term results (13-24). However, the number of patients included in each study is small from 4 to 25. Quality Appraisal In turn, data on direct comparison of surgical treatment versus percutaneous closure of SOVAs are scarce (25-27). Thus, the aim The quality appraisal was established according to Le Floch and of this systematic review and meta-analysis is to evaluate the outcomes in surgical treatment versus percutaneous closure of ruptured SOVAs.

## **Methods**

We conducted a search on PubMed and BVS Salud databases through January, 28 2021 using the MeSH term ['Sinus of Valsalva aneurysm and 'surgery' and 'percutaneous' closure'] according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) (28) (fig. 2). Two investigators working independently screened all titles and abstracts of the studies for eligibility. Duplicate citations were discarded after the preliminary search results were obtained. Furthermore, the references list of all included studies and relevant review studies were also manually searched.




Figure 2 Flow chart according to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)

### Inclusion criteria

We included in the meta-analysis only original articles that compare surgical treatment with percutaneous treatment of ruptured SOVAs

# **Exclusion criteria**

We excluded from the meta-analysis articles other than original research articles and non-English language articles.

### Data extraction

Data extraction was performed independently by two of the authors. We used standardized extraction forms that included author, year, study design, age, sex, follow-up duration, presence of major complications (residual shunt, aortic regurgitation "de novo", pericardial effusion, aneurysm recurrence), and mortality. The primary outcomes were poor outcome defined by the presence of major complications and all-cause mortality. Secondary outcomes included incidence of residual shunt, aortic regurgitation "de novo", pericardial effusion and aneurysm recurrence.

colleagues criteria. (29) This tool appraises the quality of the study based on the following questions: Did this article give an answer to the research question? Did the article focus clearly on the research question? Was the methodology appropriate? Do you believe the results? (Can it be due to chance, bias or confounding?). To be included, the article had to score "yes" on every question.

Statistical analysis: All comparisons were estimated on an intention-to-treat basis. The categorical variables were described as percentages and estimated by odds ratio (OR) with a two-tailed 95% confidence interval (CI). Continuous variables were described as mean and standard deviation and analysed by weighted mean difference (WMD). Statistic value I2 assessed by Q test was used to quantify the degree of interstudy heterogeneity. Considering the intrinsic variation in study design, we calculated the OR and WMD estimates using random-effects model for all comparisons. All P values were two-tailed, and the statistical significance was set at 0.05. Statistical analyses were performed using the Revman software package (Review Manager, Version 5.4. Copenhagen, The Nordic Cochrane Centre, the Cochrane Collaboration).

### Results

A flow diagram of study selection is shown in Figure 1. A total of 86 papers were initially identified, of which 71 non related to the theme were excluded. After review of the full texts of the 15 remaining studies, 12 were excluded based on the absence of a direct comparison of surgical treatment with percutaneous closure

Aditum Publishing -www.aditum.org



of SOVA ruptures. Thus, three articles published between 2014 significant (fig 6). and 2020 with a total of 254 patients were included in this systematic review (25-27).

Table 1 shows baseline study characteristics. Three studies including a total of 254 patients with SOVA were included in these meta-analyses. 184 patients underwent surgical correction and 70 patients underwent percutaneous correction.

Liu S et all	Xiao JW	Yang K
2014	2017	2020
35	85	134
20	56	108
15	29	26
43 (16-74)	37.6±611.9	39.2 ±
		16.1 <sup>§</sup>
		34.6 ±
		11.4 <sup>¥</sup>
23 (65,7%)	59 (69,4%)	85
		(63,4%)
(2–240)	(8–152)	1-124 §
		1-84 ¥
NR	0	53
NR	32	52
NR	40	25
NR	13	4
	2014 35 20 15 43 (16-74) 23 (65,7%) (2–240) (2–240) NR NR NR	2014 2017   35 85   20 56   15 29   43 (16-74) 37.6±611.9   23 (65,7%) 59 (69,4%)   (2-240) (8–152)   NR 0   NR 32   NR 40

Table 1 Clinical characteristic of the patients

### Outcomes

Overall poor outcome occurred in 31 patients (24 in surgical vs 7 in percutaneous group). There was a tendency for lower rate of poor outcome in percutaneous group, but with no statistical difference OR 0.75 (P= 0.51, I<sup>2</sup>=53%) (fig 3). Sub-analysis although non-significant showed an overall higher tendency for individual poor outcome in surgical group OR 1.23 (P= 0.71, I<sup>2</sup>=0%). Residual shunt (OR1.71, P=0.47, I<sup>2</sup>=0%), aortic regurgitation "de novo" (OR1.11, P=0.87), SOVA recurrence (OR4.28, P=0.31). However there was a trend towards lower tendency for pericardial effusion in the percutaneous closure group, it was non-significant (OR 0.74, P=0.71, I<sup>2</sup>=0%) (fig. 4). Publication bias analysis was assessed and can be seen on the funnel plot, showing a symmetrical distribution of the outcomes (fig 5).

When it comes to mortality patients presented an OR 0.46 (CI 95% [0.08-2.75], P=0.39,I<sup>2</sup>=0%). although higher all mortality events occurred in the surgical group, it was not statistically

	Percutaneous o		Surgical			Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% Cl
Liu S et all, 2014	1	15	6	20	39.4%	0.17 [0.02, 1.57]	
Xiao JW et al, 2017	1	29	5	56	27.1%	0.36 [0.04, 3.27]	
Yang K et al, 2020	5	26	13	108	33.5%	1.74 [0.56, 5.41]	- <b>+</b> •
Total (95% CI)		70		184	100.0%	0.75 [0.31, 1.80]	•
Total events	7		24				
Heterogeneity: Chi <sup>2</sup> =	4.26, df = 2 (P =	: 0.12); I <sup>2</sup>	= 53%				
Test for overall effect							0.01 0.1 1 10 100 Favours [ percutaneous closure ] Favours [ surgical repair ]

### Figure 3 Forest Plot Showing Overall Poor outcome

	Percutaneous o		Surgical			Odds Ratio	Odds Ratio
tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	M-H, Fixed, 95% CI
1.1.1 Residual shunt							
iu S et all, 2014.	1	15	2	20	13.7%	0.64 [0.05, 7.83]	
Kiao JW et al, 2017	1	29	0	56		5.95 [0.23, 150.67]	
/ang K et al, 2020	1	26	2	108	6.4%	2.12 [0.18, 24.32]	
Subtotal (95% CI)		70		184	22.9%	1.71 [0.40, 7.24]	
Fotal events	3		4				
Heterogeneity: Chi <sup>2</sup> =			= 0%				
Fest for overall effect:	Z = 0.72 (P = 0.	47)					
1.1.2 Aortic Regurgit	ation " <i>de novo"</i>						
iu S et all, 2014	0	15	2	20	17.9%	0.24 [0.01, 5.35]	
(iao JW et al, 2017	1	29	0	56		5.95 [0.23, 150.67]	
/ang K et al, 2020	2	26	7	108	21.5%	1.20 [0.23, 6.16]	
Subtotal (95% CI)		70		184	42.2%	1.11 [0.33, 3.70]	<b>•</b>
Fotal events	3		9				
leterogeneity: Chi <sup>2</sup> =	1.98, df = 2 (P =	: 0.37); I <sup>2</sup>	= 0%				
est for overall effect:	Z = 0.17 (P = 0.	87)					
.1.3 SOVA recurrent	e						
iu S et all, 2014.	0	15	0	20		Not estimable	
Gao JW et al, 2017	0	29	0	56		Not estimable	
fang K et al, 2020	1	26	1	108	3.2%	4.28 [0.26, 70.79]	
Subtotal (95% CI)		70		184	3.2%	4.28 [0.26, 70.79]	
lotal events	1		1				
leterogeneity: Not ap							
Test for overall effect:	Z = 1.02 (P = 0.	31)					
.1.4 Pericadial Effus	ion						
iu S et all, 2014	0	15	1	20	10.8%	0.42 [0.02, 11.03]	· · · · · ·
(iao JW et al, 2017	0	29	2	56	14.5%	0.37 [0.02, 7.95]	
rang K et al, 2020	1	26	2	108	6.4%	2.12 [0.18, 24.32]	
Subtotal (95% CI)		70		184	31.7%	0.74 [0.15, 3.67]	
Total events	1		5				
Heterogeneity: Chi <sup>2</sup> =			= 0%				
Fest for overall effect:	Z = 0.37 (P = 0.	71)					
Fotal (95% CI)		280		736	100.0%	1.23 [0.58, 2.62]	•
Fotal events	8		19				
Heterogeneity: Chi <sup>2</sup> =	5.30, df = 9 (P =	: 0.81); I <sup>2</sup>	= 0%				
est for overall effect:							0.002 0.1 1 10 51 Favours [ percutaneous closure ] Favours [ surgical repair ]
act for subarous diff	erences: Chi <sup>2</sup> = 1	1 37 df =	3(P = 0.7)	(1) $ ^2 = ($	1%		ravours ( perculareous ciosure ) ravours ( surgical repair )

Figure 4 Forest Plot - Sub-analysis showing each individual outcome




Figure 5 Funnel Plot - Risk of bias assessment, showing a symmetrical distribution of individual outcomes.




Figure 6 Forest Plot - Showing Overall Mortality

### Discussion

Traditionally, surgical repair is the main treatment option for ruptured SOVAs because of the acceptably low mortality and good long-term outcome (3-7). With the development of minimally invasive interventional technics, percutaneous closure is becoming a promising alternative to surgery in appropriately selected patients. (13-24)

In this meta-analysis we included three studies, totalling 254 patients that directly compared surgical treatment with percutaneous transcatheter closure of ruptured SOVAs. (25-27) The main results of this meta-analysis show that although not statistically significant there was a tendency for lower rate of poor outcome, defined by the presence of major complications or death, in the percutaneous group.

Residual shunt is a worrisome complication reported by several centres. (13,15,22,23) A trivial residual shunt can be detected after the procedure in up to 8% of patients undergoing percutaneous closure of ruptured SOVAs. These shunts generally disappear over time (14,15,17,19-22,24). Our meta-analysis showed that three (1.63%) of the surgically treated patients had important residual shunts. In one of these patients, the residual shunt (patch leak) was successfully treated via percutaneous with the placement of 3 occluders. (25) On the other hand, in the group of patients treated via percutaneous, one patient had a severe residual shunt with haemolysis. This patient was successfully operated one week after the percutaneous procedure. (25). All trivial shunts disappeared during follow-up period.

Aortic regurgitation (AR) "de novo" or progressive AR is another complication of both treatments and accounts for about 6,1% out Acknowledgments: nothing to declare

of 163 percutaneous treated patients. Procedure-related aortic regurgitation may be severe and of sudden onset, requiring urgent surgical repair. (21,22) Our meta-analysis shows that in surgical group nine (4.8%) patients had "de novo" AR while, in group of patients treated via percutaneous only three (4,2%) had this complication. In percutaneous group one patient develop severe occluder-related "de novo" AR and was sent to surgery (26). The remainders "de novo" AR were trivial.

Our study showed that six patient had pericardial effusion, five (2.71%) in surgical group in three of which pericardiocentesis was performed, and one (1.4%) patient in patients treaded percutaneously.

Our meta-analysis showed that there was no occluders' migration, which contrasts with what has been reported in patients underwent percutaneous closure of ruptured SOVAs published in other series (21, 22, 24)

In long-term follow-up, the recurrence of SOVA has been reported in several studies, both in surgical series (3) and in percutaneous treatment series. (21,24) The present meta-analysis shows that recurrence of SOVA occurs in one patient in each group, suggesting that such recurrence might be independent of the choice of the treatment (27).

Our meta-analysis shows that three perioperative deaths (1,6%) occur in surgical group: Two patients died of low cardiac output syndrome (25,26) and one patient died of respiratory failure (26). Furthermore, in follow up period another two (1,0%) patients died in surgical group: one patient died of infective endocarditis (26) and other patient died 74 months after surgery of unknown causes. (27). On the other hand, no early or late deaths in percutaneous treated group occurred. These results regarding to mortality are consistent with those reported in several studies. In percutaneous treated patients the early mortality is null (13-24), while early mortality in patients with surgically treated ruptured SOVA although low, it still exist. (2-7).

The studies included in our meta-analysis were not randomized, so it is not possible to exclude bias in the results. It is known that patients with other associated cardiac malformations are treated surgically. While patients treated percutaneously are carefully chosen. Contra-indication for this type of treatment are related to size of the defect, and to presence of concomitant pathologies such as large ventricular septal defect, severe aortic regurgitation or suspected infective endocarditis (15,30)

### Conclusions

In conclusion, our meta-analysis showed that when compared to surgical treatment the percutaneous closure of ruptured SOVAs is safe and effective, being an excellent alternative in selected patients. Randomized studies comparing the two types of treatment should be done to better demonstrate the real importance of percutaneous treatment of this pathology.

### **Declarations**

Financing: nothing to declare

Competition of interests: The authors declare no conflicts of interest.

Author's contribution

Study design: HM Data collection: HM and TN Writing of the manuscript: HM and HF Revisions and approval of the final manuscript: All authors Supervision: HM

# References

- Wang KY, Sutton MSJ, Ho HY, Ting CT. Congenital sinus 18. 1. of Valsalva aneurysm: A multiplane transesophageal echocardiographic experience. J Am Soc Echocardiogr 1997; **10**: 956–963.
- Wang ZJ, Zou CW, Li DC. Surgical repair of sinus of 19. Valsalva aneurysm in Asian patients. Ann Thorac Surg 2007; **84**: 156–160.
- 3. Luo X, Zhang D, Li B, Qi L, Gong L, Tang Y et al. Surgical repair of a ruptured congenital sinus of Valsalva aneurysm: 10-year experience with 286cases. Eur J Cardiothorac Surg 20. Fang ZF, Huang YY, Tang L, Hu XQ, Shen XQ, Tang JJ, 2019;55:1211-8.
- Choudhary SK, Bhan A, Sharma R. Sinus of Valsalva aneurysm: 20 years' experience. J Card Surg 1997; 12: 300-308.
- Takach TJ, Reul GJ, Duncan JM. Sinus of Valsalva aneurysm or fistula: management and outcome. Ann Thorac Surg 1999; **68**: 1573–1577.
- Vural KM, Sener E, Tasdemir O, Bayasit K. Approach to 6. sinus of Valsalva aneurysm: a review of 53 cases. Eur J Cardiothorac Surg 2001; 20: 71-716.
- Dong C, Wu QY, Tang Y. Ruptured sinus of Valsalva 7. aneurysm: A Beijing Experience. Ann Thorac Surg 2002; 74: 1621-1624.
- 8. Karbhase JN, Sinha P, Joshi P, Doshi C, Nagle KN. Unruptured aneurysms of the sinus of Valsalva into the 23. pulmonary artery presenting with right ventricular outflow tract obstruction. Internet J Thorac Cardiovasc Surg 2003; **19**: 145–146.
- Pepper C, Munsh C, Sivanantham UM, Pye M. Unruptured 9. aneurysm of the left sinus of Valsalva extending into the left ventricular outflow tract: Presentation and imaging. Heart 24. 1998; 80: 190-193.
- 10. Pigula FA, Griffith BP, Kormos RL. Massive sinus of Valsalva aneurysm presenting with coronary insufficiency. Ann Thorac Surg 1997; 64: 1475-1476.
- 11. Choudhary SK, Bhan A, Reddy SCR. Aneurysm of sinus of Valsalva dissecting into interventricular septum. Ann Thorac Surg 1998; 65:735-740.
- 12. Cullen S, Somerville J, Redingtom A. Transcatheter closure of a ruptured aneurysm of the sinus of Valsalva. Br HeartJ 1994;71:479-480
- 13. Arora R, Trehan V, Rangasetty UM, Mukhopadhyay S, Thakur AK, Kalra GS. Transcatheter closure of ruptured 27. sinus of Valsalva aneurysm. J Interv Cardiol 2004;17:53e58.
- 14. Chang CW, Chiu SN, Wu ET, Tsai SK, Wu MH, Wang JK. Transcatheter closure of a ruptured sinus of Valsalva aneurysm. Circ J2006;70:1043e1047.
- 15. Kerkar PG, Lanjewar CP, Mishra N, Nyayadhish P, Mammen I. Transcatheter closure of ruptured sinus of Valsalva aneurysm using the Amplatzer duct occluder: immediate 29. Le Floch B, et al. Which positive factors determine the

J results and mid-term follow-up. Eur Heart 2010;31:2881e2887.

- 16. Sen S, Chattopadhyay A, Ray M, Bandyopadhyay B. Transcatheter device closure of ruptured sinus of Valsalva: immediate results and short term follow up. Ann Pediatr Cardiol 2009;2:79e82.
- 17. Szkutnik M, Kusa J, Glowacki J, Fiszer R, Bialkowski J. Transcatheter closure of ruptured sinus of Valsalva aneurysms with an Amplatzer occluder. Rev Esp Cardiol 2009;62:1317e1321.
- Tong S, Zhong L, Liu J, Yao Q, Shu M, Song Z. The immediate and follow-up results of transcatheter occlusion of the ruptured sinus of Valsalva aneurysm with duct occluder. J Invasive Cardiol 2014;26: 55e59.
- Zhao SH, Yan CW, Zhu XY, Li JJ, Xu NX, Jiang SL, Xu ZY, Wang C, Wu WH, Hai-Bo H, Li SG, Ye ZK, Wang H. Transcatheter occlusion of the ruptured sinus of Valsalva aneurysm with an Amplatzer duct occluder. Int J Cardiol 2008;129:81e85.
- Zhou SH. Long-term outcomes of transcatheter closure of ruptured sinus valsalva aneurysms using patent ductus arteriosus occluders. Circ J. 2014;78(9):2197-202.
- 21. Galeczka M, Glowacki J, Yashchuk N, Ditkivskyy I, Rojczyk D, Knop M, Smerdzinski S, Cherpak B, Szkutnik M, Bialkowski J, Fiszer R, Lazoryshynets V. Medium- and longterm follow-up of transcatheter closure of ruptured sinus of Valsalva aneurysm in Central Europe population, J Cardiol. 2019 Oct;74(4):381-387.
- 22. Mahimarangaiah J, Chandra S, Subramanian A, Srinivasa KH, Usha MK, Manjunath CN. Transcatheter closure of ruptured sinus of Valsalva: Different techniques and midterm follow-up. Catheter Cardiovasc Interv. 2016 Feb 15;87(3):516-22.
- Sinha SK, Khanna NN, Razi M, Krishna V, Jha MJ, Mishra V, Aggarwal P, Goel A, Singh K, Thakur R, Rajan L, Varma CM. Safety and Feasibility of Transcatheter Interruption of Ruptured Sinus of Valsalva Aneurysm Using the Cocoon Duct Occluder: Immediate Results and Mid-Term Follow-Up. Cardiol Res. 2017 Aug;8(4):154-160.
- Zhong L, Tong SF, Zhang Q, Zhang ZH, Yao Q, Li YH, Zhang WH, Song ZY. Clinical efficacy and safety of transcatheter closure of ruptured sinus of Valsalva aneurysm. Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1184-9
- 25. Liu S, Xu X, Ding X, Liu G, Zhao X, Qin Y. Comparison of immediate results and mid-term follow up of surgical and percutaneous closure of ruptured sinus of Valsalva aneurysm. J Cardiol 2014;63:239e243
- Xiao JW, Wang QG, Zhang DZ, Cui CS, Han X, Zhang P, 26. Hou C, Zhu XY. Clinical outcomes of percutaneous or surgical closure of ruptured sinus of Valsalva aneurysm. Congenit Heart Dis. 2018;13(2):305-310.
- Yang K, Wei MD, Geng WL, Hu HB, Xu ZY, Zhang GJ, Zhao SH. Safety and efficacy of percutaneous closure of ruptured sinus of Valsalva aneurysm. EuroIntervention. 2018 Dec 20;14(12):e1288-e1294.
- 28. Moher D, et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med. 2009; 151: 264-9..

GP satisfaction in clinical practice? A systematic literature review. BMC Fam Pract. 2016; 17: 133.

 Kerkar PG. Ruptured sinus of Valsalva aneurysm: Yet another hole to plug! Ann Pediatr Cardiol. 2009 Jan;2(1):83-4.